Express News | Clene Inc. - Has Regained Compliance With Nasdaq Listing Rule 5550(a)(2) for Continued Listing on Nasdaq
Optimistic Outlook on Clene's CNM-Au8 for ALS Amid Anticipated Regulatory Milestones
Express News | Clene Inc. : Canaccord Genuity Adjusts Target Price to $94 From $5 to Reflect 1-for-20 Reverse Stock Split
Clene to Present at the Emerging Growth Conference
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Nasdaq Dips Over 300 Points; PepsiCo Reports Weak Sales
Express News | Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection With Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for Cnm-AU8® in ALS
Express News | Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection With Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8 in ALS
Express News | Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Clene To Carry Out 1-for-20 Reverse Stock Split On July 11th, 2024
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Crude Oil Down 1%; Soligenix Shares Surge
Express News | Clene Inc. Announces 1-for-20 Reverse Stock Split Effective July 11, 2024; To Begin Trading On Split-Adjusted Basis At Market Open
Express News | Clene Inc. - to Effect 1-for-20 Reverse Stock Split on July 11
Clene Announces 1-for-20 Reverse Stock Split
FDA Revokes Use of Brominated Vegetable Oil in Food
Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference
Clene Says Lead Drug Candidate Shows Potential to Treat Rett Syndrome
Clene Presents Preliminary Data for CNM-Au8 as a Potential Treatment for Rett Syndrome
No Data